Approximately 530 Alabama independent drug store owners are seeking relief of as much as $5,000 per store per year in business license fees by excluding prescription sales from gross receipts, according to a report published Friday by the Alabama Media Group. State legislation has been introduced to that end, but is opposed by local municipalities looking at stark revenue reductions. "Cities like Montgomery and Mobile claim the hit would be excessive," the report noted. "In Mobile, city officials estimate that computing a store's gross sales by including prescription medicine has brought in an average of $465,000 annually for the past five years." (AL.com)
DIRs are as much about patient access as it is about pharmacy business issues.
The defendants marketed their products with claims that they could treat medical conditions such as cancer, cardiovascular disease, multiple sclerosis, autism, bipolar disorder, brain injury and epilepsy.
President’s first choice for the position, Andy Puzder, withdrew his name from consideration following criticism he faced about his opposition to raising the minimum wage.
Walgreens Boots Alliance, Rite Aid, Walmart and Target had already joined the Americans for Affordable Products coalition in an effort to stop the BAT.
The partnership will give NPA members preferential access for their manufacturing facilities to become Informed-Choice Certified sites, NPA noted.
Its new identity will improve recognition that the generic and biosimilar medicines industry is one of “the nation's great health care success stories, and that competition from generics and biosimilars lowers the cost of medicine.”
ILI nationwide reached 4.8%, well above the national baseline of 2.2% and a sharp uptick in the 3.9% in ILI reported the week prior.
Noting that Price will play a key role in selecting the next commissioner for the Food and Drug Administration, the Consumer Healthcare Products Associaton offered several qualities that would embody an ideal candidate.
U.S. District Judge Josephine Staton for the Central District of California entered a consent decree of permanent injunction yesterday between the United States and VivaCeuticals, doing business as Regeneca Worldwide.